Pharmaceutical Policy Reforms to Regulate Drug Prices in Asia Pacific Region

The Case of Australia, China, India, Malaysia, New Zealand, and South Korea

Syed Shahzad Hasan, Chia Siang Kow, Dalia Dawoud, Omneya Mohamed, Darrin Baines, Zaheer Ud Din Babar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of pharmaceutical spending is through out-of-pocket payment, such as in the Asia Pacific region. We have undertaken a detailed appraisal of the pharmaceutical policy reforms to regulate drug prices in 3 developed (Australia, New Zealand, and South Korea) and 3 emerging (China, India, and Malaysia) economies of the Asia Pacific region. Despite continuous efforts by the authorities in adopting a wide range of reformatory pharmaceutical pricing policies to ensure affordability of medicines, these policies may not be optimal where drug prices were not lowered as expected (eg, in Korea). On the contrary, considerable price reductions of various pharmaceuticals have been observed in New Zealand and India because of the reform in pharmaceutical pricing policy. This review of pharmaceutical pricing reforms reinforces the need for constant monitoring by policy makers in Asia Pacific countries to regulate drug prices and to undertake reform in pharmaceutical pricing policies when necessary to ensure affordability and access to medicines.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalValue in Health Regional Issues
Volume18
Early online date7 Nov 2018
DOIs
Publication statusPublished - 1 May 2019

Fingerprint

Republic of Korea
Drug and Narcotic Control
Malaysia
New Zealand
India
China
Pharmaceutical Preparations
Costs and Cost Analysis
Korea
Health Expenditures
Administrative Personnel
Policy reform
Drugs
Pharmaceuticals
Asia-Pacific region
South Korea
Medicine
Pharmaceutical pricing
Affordability
Pricing policy

Cite this

@article{63c88149571849cb98ba8e945e488ff7,
title = "Pharmaceutical Policy Reforms to Regulate Drug Prices in Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea",
abstract = "Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of pharmaceutical spending is through out-of-pocket payment, such as in the Asia Pacific region. We have undertaken a detailed appraisal of the pharmaceutical policy reforms to regulate drug prices in 3 developed (Australia, New Zealand, and South Korea) and 3 emerging (China, India, and Malaysia) economies of the Asia Pacific region. Despite continuous efforts by the authorities in adopting a wide range of reformatory pharmaceutical pricing policies to ensure affordability of medicines, these policies may not be optimal where drug prices were not lowered as expected (eg, in Korea). On the contrary, considerable price reductions of various pharmaceuticals have been observed in New Zealand and India because of the reform in pharmaceutical pricing policy. This review of pharmaceutical pricing reforms reinforces the need for constant monitoring by policy makers in Asia Pacific countries to regulate drug prices and to undertake reform in pharmaceutical pricing policies when necessary to ensure affordability and access to medicines.",
keywords = "Access, Affordability, Asia, Pacific, Pharmaceutical, Policy, Pricing",
author = "Hasan, {Syed Shahzad} and Kow, {Chia Siang} and Dalia Dawoud and Omneya Mohamed and Darrin Baines and Babar, {Zaheer Ud Din}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.vhri.2018.08.007",
language = "English",
volume = "18",
pages = "18--23",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",

}

Pharmaceutical Policy Reforms to Regulate Drug Prices in Asia Pacific Region : The Case of Australia, China, India, Malaysia, New Zealand, and South Korea. / Hasan, Syed Shahzad; Kow, Chia Siang; Dawoud, Dalia; Mohamed, Omneya; Baines, Darrin; Babar, Zaheer Ud Din.

In: Value in Health Regional Issues, Vol. 18, 01.05.2019, p. 18-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmaceutical Policy Reforms to Regulate Drug Prices in Asia Pacific Region

T2 - The Case of Australia, China, India, Malaysia, New Zealand, and South Korea

AU - Hasan, Syed Shahzad

AU - Kow, Chia Siang

AU - Dawoud, Dalia

AU - Mohamed, Omneya

AU - Baines, Darrin

AU - Babar, Zaheer Ud Din

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of pharmaceutical spending is through out-of-pocket payment, such as in the Asia Pacific region. We have undertaken a detailed appraisal of the pharmaceutical policy reforms to regulate drug prices in 3 developed (Australia, New Zealand, and South Korea) and 3 emerging (China, India, and Malaysia) economies of the Asia Pacific region. Despite continuous efforts by the authorities in adopting a wide range of reformatory pharmaceutical pricing policies to ensure affordability of medicines, these policies may not be optimal where drug prices were not lowered as expected (eg, in Korea). On the contrary, considerable price reductions of various pharmaceuticals have been observed in New Zealand and India because of the reform in pharmaceutical pricing policy. This review of pharmaceutical pricing reforms reinforces the need for constant monitoring by policy makers in Asia Pacific countries to regulate drug prices and to undertake reform in pharmaceutical pricing policies when necessary to ensure affordability and access to medicines.

AB - Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of pharmaceutical spending is through out-of-pocket payment, such as in the Asia Pacific region. We have undertaken a detailed appraisal of the pharmaceutical policy reforms to regulate drug prices in 3 developed (Australia, New Zealand, and South Korea) and 3 emerging (China, India, and Malaysia) economies of the Asia Pacific region. Despite continuous efforts by the authorities in adopting a wide range of reformatory pharmaceutical pricing policies to ensure affordability of medicines, these policies may not be optimal where drug prices were not lowered as expected (eg, in Korea). On the contrary, considerable price reductions of various pharmaceuticals have been observed in New Zealand and India because of the reform in pharmaceutical pricing policy. This review of pharmaceutical pricing reforms reinforces the need for constant monitoring by policy makers in Asia Pacific countries to regulate drug prices and to undertake reform in pharmaceutical pricing policies when necessary to ensure affordability and access to medicines.

KW - Access

KW - Affordability

KW - Asia

KW - Pacific

KW - Pharmaceutical

KW - Policy

KW - Pricing

UR - http://www.scopus.com/inward/record.url?scp=85056176388&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2018.08.007

DO - 10.1016/j.vhri.2018.08.007

M3 - Article

VL - 18

SP - 18

EP - 23

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

ER -